ADEFOVIR DIPIVOXIL pharmaceutical API fine chemical suppliers

Subscribe to access the full database, or Start Trial
Vendor	Vendor Homepage	Vendor Sku	API Url
Hangzhou APIChem Technology	⤷ Start Trial	AC-1693	⤷ Start Trial
AKos Consulting & Solutions	⤷ Start Trial	AKOS005145737	⤷ Start Trial
Amadis Chemical	⤷ Start Trial	A807894	⤷ Start Trial
TCI (Tokyo Chemical Industry)	⤷ Start Trial	A2414	⤷ Start Trial
BioChemPartner	⤷ Start Trial	BCPP000434	⤷ Start Trial
>Vendor	>Vendor Homepage	>Vendor Sku	>API Url

Last updated: February 19, 2026

This report identifies key bulk Active Pharmaceutical Ingredient (API) sources for adefovir dipivoxil, analyzes their manufacturing capabilities, regulatory standing, and supply chain considerations. The objective is to provide actionable intelligence for R&D and investment decisions within the pharmaceutical sector.

What is Adefovir Dipivoxil?

Adefovir dipivoxil is a prodrug of adefovir, a nucleotide analog reverse transcriptase inhibitor. It is primarily used in the treatment of chronic hepatitis B virus (HBV) infection. The drug works by inhibiting HBV DNA polymerase, thereby reducing viral replication. Its chemical structure is (9-[2-(Bis{[(isopropoxycarbonyl)oxy]methyl}phosphinoyl)methoxy]ethyl)adenine bis(pivaloyloxymethyl) ester. The efficacy and safety profile of adefovir dipivoxil have led to sustained market demand, necessitating a robust and reliable API supply chain.

Key API Manufacturers and Their Capabilities

Several manufacturers globally specialize in the production of adefovir dipivoxil API. These entities vary in scale, technological expertise, and regulatory compliance.

Primary API Suppliers

The following companies are identified as significant suppliers of adefovir dipivoxil API:

Gland Pharma Limited (India): Known for its robust manufacturing infrastructure and diverse product portfolio. Gland Pharma is a significant player in the generics API market.
Hetero Labs Limited (India): A vertically integrated pharmaceutical company with strong R&D and manufacturing capabilities. Hetero is a major producer of APIs for various therapeutic areas.
Zydus Lifesciences Limited (formerly Cadila Healthcare) (India): A global pharmaceutical company with a strong presence in API manufacturing. Zydus has a well-established quality management system.
Divi's Laboratories Limited (India): Specializes in custom synthesis and the large-scale manufacturing of APIs. Divi's is recognized for its efficiency and cost-effectiveness.
Aurobindo Pharma Ltd. (India): A leading generic pharmaceutical company with significant API manufacturing capacity. Aurobindo's focus on quality and compliance is a key strength.

Manufacturing Process Considerations

The synthesis of adefovir dipivoxil typically involves multi-step chemical processes. Key stages include the synthesis of the adefovir base, followed by esterification and prodrug formation. Manufacturers must adhere to strict Good Manufacturing Practices (GMP) to ensure API purity, potency, and consistency. Critical aspects of the manufacturing process include:

Chiral Purity: Ensuring the correct stereochemistry of the active molecule.
Impurity Profiling: Rigorous control and identification of process-related impurities and degradation products.
Yield Optimization: Efficient synthesis pathways to manage production costs.
Scale-Up Capabilities: Ability to produce API in commercial quantities to meet market demand.

Regulatory Landscape and Compliance

The regulatory status of an API manufacturer is paramount for pharmaceutical companies relying on their supply. Key regulatory bodies and their requirements include:

U.S. Food and Drug Administration (FDA): Manufacturers supplying to the U.S. market must undergo FDA inspections and have their facilities listed in the FDA’s Drug Master File (DMF) system. Compliance with 21 CFR Part 210 and 211 is mandatory.
European Medicines Agency (EMA): For the European market, API manufacturers must comply with EU GMP guidelines and have a Certificate of Suitability to the monographs of the European Pharmacopoeia (CEP) or an active DMF.
Other National Regulatory Agencies: Manufacturers supplying to other regions must comply with local regulations and pharmacopoeial standards (e.g., PMDA in Japan, TGA in Australia).

FDA DMF Filings

A critical indicator of regulatory compliance and market readiness is the submission and acceptance of Drug Master Files (DMFs). While specific active DMFs for adefovir dipivoxil API are proprietary information held by manufacturers, the presence of a DMF signifies a commitment to regulatory scrutiny. Companies with publicly accessible information on their DMF filings often include:

Gland Pharma Limited: Known to maintain a comprehensive DMF portfolio across its product range.
Hetero Labs Limited: Actively files DMFs with major regulatory agencies for its key APIs.
Zydus Lifesciences Limited: Possesses a strong track record of successful DMF submissions.

The status of these DMFs (e.g., active, pending) directly impacts the ability of a finished dosage form manufacturer to gain regulatory approval in specific markets.

GMP Compliance and Audits

Manufacturers undergo regular audits from regulatory bodies and their clients. A history of successful GMP audits is indicative of a mature quality management system. Key compliance metrics include:

Number of FDA Inspections: A higher number of successful inspections without significant findings suggests robust operational controls.
CEP Status: For European markets, holding a CEP is a significant advantage, indicating compliance with European Pharmacopoeia standards.
Client Audits: Successful audits by major pharmaceutical clients are a strong endorsement of manufacturing quality.

Supply Chain and Geopolitical Considerations

The global supply chain for pharmaceutical APIs is subject to various risks, including geopolitical instability, trade policies, and logistics challenges.

Geographic Concentration of Manufacturing

India is a dominant global hub for API manufacturing, including adefovir dipivoxil. This concentration presents both advantages (cost-effectiveness, scale) and disadvantages (dependency, potential for supply disruptions due to regional issues).

Risk Mitigation Strategies

Companies sourcing adefovir dipivoxil API should consider:

Dual Sourcing: Establishing relationships with at least two qualified API manufacturers in different geographic locations to mitigate single-point-of-failure risks.
Supply Chain Transparency: Ensuring deep visibility into the entire API supply chain, including raw material origins.
Inventory Management: Maintaining adequate buffer stock of API to account for unforeseen delays.
Contractual Agreements: Robust contracts with clear terms regarding quality, delivery schedules, and force majeure clauses.

Market Trends and Demand Analysis

The demand for adefovir dipivoxil API is influenced by the prevalence of chronic hepatitis B and the availability of alternative treatments.

Hepatitis B Prevalence

Globally, an estimated 296 million people lived with chronic HBV infection in 2019, according to the World Health Organization (WHO) [1]. While newer, more potent antivirals exist, adefovir dipivoxil remains a viable treatment option, particularly in regions where cost is a significant factor.

Competition and Generic Entry

The patent expiry for adefovir dipivoxil has led to the entry of multiple generic manufacturers. This has increased competition among API suppliers, potentially driving down prices but also emphasizing the need for consistent quality and regulatory compliance.

Key Takeaways

Indian Dominance: India is the primary manufacturing hub for adefovir dipivoxil API, with companies like Gland Pharma, Hetero Labs, Zydus Lifesciences, Divi's Laboratories, and Aurobindo Pharma being key suppliers.
Regulatory Prerequisite: For market access in regulated regions like the US and EU, API manufacturers must possess active Drug Master Files (DMFs) and comply with stringent Good Manufacturing Practices (GMP) as verified by regulatory agencies (FDA, EMA).
Supply Chain Risk: The geographic concentration of API manufacturing in India necessitates dual-sourcing strategies and robust inventory management to mitigate supply chain disruptions.
Market Dynamics: Demand for adefovir dipivoxil API is sustained by the global prevalence of chronic hepatitis B, though competition from newer antivirals and generic products shapes pricing and market access.

Frequently Asked Questions

What are the primary quality standards for adefovir dipivoxil API? API must meet pharmacopoeial standards, such as those in the United States Pharmacopeia (USP) or European Pharmacopoeia (Ph. Eur.), with specific limits on impurities, assay, and physical characteristics.
How does the regulatory status of an API manufacturer impact finished drug product approval? A regulatory agency's acceptance of an API manufacturer's DMF and its GMP compliance record is a prerequisite for the approval of any finished drug product relying on that API.
What are the implications of geopolitical events on adefovir dipivoxil API supply chains? Geopolitical events can lead to trade restrictions, transportation disruptions, and increased raw material costs, potentially impacting API availability and pricing.
Are there significant differences in the manufacturing processes used by various adefovir dipivoxil API suppliers? While the core synthetic route is generally similar, variations may exist in catalyst usage, purification techniques, and impurity control strategies, leading to differences in yield and cost.
What is the typical lead time for securing large commercial quantities of adefovir dipivoxil API from a new supplier? Lead times can range from 3 to 9 months, depending on the supplier's existing production schedule, the complexity of their validation processes, and the required order volume.

Citations

[1] World Health Organization. (2022). Hepatitis B. https://www.who.int/news-room/fact-sheets/detail/hepatitis-b

Bulk Pharmaceutical API Sources for ADEFOVIR DIPIVOXIL